Stocks · Health care · Biological Products, (No Diagnostic Substances)

Vir Biotechnology, Inc.

VIR Clue Score34

United States Fiscal year ends December CIK 0001706431 Results filed 4 Nov 2026

Add to watchlist

What the insiders did Net selling

By person

37 insiders · 462 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

SVF Endurance (Cayman) Ltd entity

10% owner

$19.00M (1)

$187.45M (143)

−$168.45M

36,345,590

21.48%

$403.44M

+60.7%

Alaska Permanent Fund Corp entity

10% owner

$30.00M (1)

—

+$30.00M

16,666,668

9.85%

$185.00M

+50.0%

Abu Dhabi Investment Authority

Former 10% Owner

$20.00M (1)

—

+$20.00M

3,666,666

2.17%

$40.70M

—

ARCH Venture Partners IX, LLC entity

10% owner

$20.00M (1)

—

+$20.00M

12,321,218

7.28%

$136.77M

—

Kristina Burow

Director

$20.00M (1)

—

+$20.00M

1,000,000

0.5910%

$11.10M

—

Robert Nelsen

Director

$20.00M (1)

—

+$20.00M

12,847,529

7.59%

$142.61M

—

Vicki L Sato

Director

—

$13.98M (53)

−$13.98M

1,078,391

0.6373%

$11.97M

−35.4%

Herbert Virgin

EVP, Research & CSO

—

$11.69M (62) scheduled

−$11.69M

262,500

0.1551%

$2.91M

—

Phillip Pang

EVP & Chief Medical Officer

—

$11.02M (64) scheduled

−$11.02M

250,111

0.1478%

$2.78M

+3,116%

Jay Parrish

Chief Business Officer

—

$10.69M (12) scheduled

−$10.69M

9,260

0.0055%

$102.79K

0.0%

Temasek Holdings (Private) Ltd entity

10% owner

$10.00M (1)

—

+$10.00M

5,499,999

3.25%

$61.05M

—

Howard Horn

CFO

—

$4.73M (12)

−$4.73M

230,712

0.1363%

$2.56M

−16.9%

Robert J More

Director

—

$3.44M (12)

−$3.44M

1,044,684

0.6174%

$11.60M

—

George A Scangos

Director

—

$3.09M (14)

−$3.09M

3,757,298

2.22%

$41.71M

−32.5%

Backer Marianne De

President and CEO

—

$2.26M (6) scheduled

−$2.26M

1,001,263

0.5917%

$11.11M

—

Steven J. Rice

Chief Administrative Officer

—

$1.22M (7) scheduled

−$1.22M

106,840

0.0631%

$1.19M

+5,091%

Saira Ramasastry

Director

—

$761.09K (5) scheduled

−$761.09K

22,619

0.0134%

$251.07K

—

Ann M. Hanly

EVP & Chief Technology Officer

$499.85 (1)

$473.24K (6) scheduled

−$472.74K

117,913

0.0697%

$1.31M

+10,316%

Verneuil Vanina de

EVP, General Counsel, Corp Sec

—

$453.03K (13) scheduled

−$453.03K

110,193

0.0651%

$1.22M

+58.1%

Janet Napolitano

Director

—

$281.19K (5) scheduled

−$281.19K

21,216

0.0125%

$235.50K

—

Charles Elliott Sigal

Director

$246.34K (4)

—

+$246.34K

49,806

0.0294%

$552.85K

—

Brent Sabatini

SVP, Chief Accounting Officer

—

$142.14K (7) scheduled

−$142.14K

61,902

0.0366%

$687.11K

+88.1%

Mark Eisner

EVP and Chief Medical Officer

—

$106.31K (5) scheduled

−$106.31K

154,024

0.0910%

$1.71M

—

Jason O'Byrne

EVP & Chief Financial Officer

—

$68.93K (3) scheduled

−$68.93K

162,615

0.0961%

$1.81M

+5,084%

Sung Lee

EVP & Chief Financial Officer

—

$59.40K (1)

−$59.40K

100,492

0.0594%

$1.12M

—

Johanna Friedl-Naderer

EVP & Chief Operating Officer

—

$33.82K (1)

−$33.82K

148,518

0.0878%

$1.65M

—

Bill & Melinda Gates Foundation entity

10% owner

—

—

—

2,777,777

1.64%

$30.83M

—

Q-Ventures Program II (Co-Invest Holdings) Ltd. entity

Former 10% Holder

—

—

—

1,666,666

0.9849%

$18.50M

—

Klaus Frueh

Director

—

—

—

440,621

0.2604%

$4.89M

+98.3%

Phillip A Sharp

Director

—

—

—

165,618

0.0979%

$1.84M

—

Jeffrey S. Hatfield

Director

—

—

—

39,806

0.0235%

$441.85K

—

Ramy Farid

Director

—

—

—

32,000

0.0189%

$355.20K

—

Norbert W Bischofberger

Director

—

—

—

32,000

0.0189%

$355.20K

—

Timothy Coughlin

Director

—

—

—

16,000

0.0095%

$177.60K

—

Robert J Perez

Director

—

—

—

15,806

0.0093%

$175.45K

—

Suzanne Louise Topalian

Director

—

—

—

12,731

0.0075%

$141.31K

—

Dipchand Nishar

Director

—

—

—

3,374

0.0020%

$37.45K

—